Irish biophotonics SME building near-infrared optical systems for non-invasive clinical monitoring in ICU and neonatal brain imaging.
BIOPIXS is an Irish deep-tech SME specialising in biophotonic instrumentation — specifically near-infrared spectroscopy (NIRS) and diffuse optical imaging systems for non-invasive clinical monitoring. Their technology measures tissue oxygenation, cerebral blood flow, and microvascular function at the bedside without requiring blood samples or invasive probes. In EU projects they act as technology providers, integrating their optical sensing hardware and signal-processing capabilities into clinical research platforms. Their work bridges photonics engineering and biomedical applications, making complex optical measurements accessible in hospital and intensive-care settings.
NIRS is the core enabling technology across both VASCOVID (microvascular oxygenation in ICU) and TinyBrains (cerebral blood flow in infant brains), confirming it as the organisation's defining capability.
TinyBrains explicitly targets bio-photonic imaging of the infant brain using diffuse optics, while VASCOVID applies the same optical physics to vascular endothelial assessment.
VASCOVID's objective was a portable platform for microvascular health assessment directly in intensive-care units, indicating hardware miniaturisation and clinical deployment know-how.
TinyBrains extends BIOPIXS's optical toolset into paediatric neuroscience, adding EEG integration, cerebral blood flow quantification, and neurodevelopmental outcome tracking for infants with congenital heart defects.
VASCOVID addressed cardio-pulmonary interactions, ventilator weaning decisions, and endothelial dysfunction in COVID-19 ICU patients — demonstrating applied understanding of intensive-care clinical workflows.
BIOPIXS entered H2020 through VASCOVID (2020), applying NIRS to a pressing clinical need: assessing microvascular damage and guiding ventilator weaning in COVID-19 ICU patients — a focused adult critical-care application. By 2021 they had moved into TinyBrains, shifting the same optical physics toward a substantially more complex challenge: imaging the developing infant brain and linking cellular brain damage in babies with congenital heart defects to long-term neurodevelopmental outcomes. The underlying photonics expertise is consistent, but the clinical domain has migrated from emergency adult medicine toward paediatric neuroscience and neonatal intensive care — a higher-value, longer research horizon.
BIOPIXS is moving deeper into paediatric and neonatal clinical research, suggesting future collaboration opportunities will likely involve infant brain health, neonatal ICU monitoring, and neurodevelopmental outcome studies rather than general adult critical care.
BIOPIXS has participated in both of its H2020 projects as a partner, not a coordinator — a pattern consistent with an early-stage technology SME that brings a specific optical instrumentation capability to clinically-led consortia. Their network of 11 partners across 4 countries across just two projects suggests active multi-partner engagement rather than isolated bilateral arrangements. Working with them likely means integrating their NIRS hardware or software components into a larger clinical or engineering work package, with BIOPIXS handling the photonics-specific tasks.
BIOPIXS has built connections with 11 unique partners across 4 countries in only two projects, suggesting a collaborative model that draws in diverse clinical and technical partners for each application. Their Irish base (Cork) combined with multi-country participation points to a European-facing research network despite their small size.
BIOPIXS occupies a narrow but high-value niche: they are one of very few SMEs translating advanced diffuse optics and NIRS from physics labs into real clinical environments — ICUs and neonatal wards. Unlike academic photonics groups, they bring hardware that works at the bedside; unlike large medtech companies, they operate at the frontier of clinical research where commercial products do not yet exist. For a consortium needing credible biophotonic measurement capability without building it from scratch, BIOPIXS offers ready expertise and a track record in two distinct clinical settings.
